This article will be permanently flagged as inappropriate and made unaccessible to everyone. Are you certain this article is inappropriate? Excessive Violence Sexual Content Political / Social
Email Address:
Article Id: WHEBN0026756401 Reproduction Date:
Elzasonan (CP-448,187) is a selective 5-HT1B and 5-HT1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy.[1][2][3][4][5] By preferentially blocking 5-HT1B and 5-HT1D autoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects.[3]
: PSO/PSI
(, , , , , , ), /,
proc (/), drug (/////)
Sociology, Social psychology, Memory, Experimental psychology, Psychology
5-Methoxytryptamine, Metitepine, Lysergic acid diethylamide, Bromocriptine, Methysergide
5-Carboxamidotryptamine, Metitepine, Lysergic acid diethylamide, Bromocriptine, Methysergide
Medicine, Schizophrenia, Psychology, Psychotherapy, Neuroimaging
International Union of Pure and Applied Chemistry nomenclature, Regulation of therapeutic goods, CAS registry number, Anatomical Therapeutic Chemical Classification System, PubChem
5-Carboxamidotryptamine, 5-Methoxytryptamine, Metitepine, Lysergic acid diethylamide, Bromocriptine